Nintedanib in lung cancer: Added benefit depends on disease severity

9 abril 2015

In non-small cell lung cancer the new angiokinase inhibitor has advantages in patients without brain metastases, but disadvantages in patients with brain metastases. In principle, at most an indication of an added benefit can be derived from the results of the only study included in the manufacturer dossier. As the analysis of the data shows, the advantages or disadvantages of nintedanib in combination with docetaxel primarily depend on whether patients already had brain metastases at the start of the study or not.